Dipyrone (metamizole)

Stamer, Ulrike; Gundert‐Remy, Ursula; Biermann, Elmar; Erlenwein, Joachim; Meiβner, W; Wirz, Stefan; Stammschulte, Thomas

doi:10.1007/s00482-016-0160-3

Cited by 43 publications

(18 citation statements)

References 25 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared to nonsteroidal anti-inflammatory drugs (NSAIDs) or opioids, metamizole seems to display a favorable profile of renal and gastrointestinal risks [3,4]. Yet, the safety of metamizole has been the topic of a lengthy and controversial debate due to the possibility of agranulocytosis as a grave and potentially fatal adverse effect [3,[5][6][7]. Although the true incidence of metamizole-induced agranulocytosis is unclear and varies widely between studies [8][9][10][11][12], many countries including the UK, France, Norway, Sweden, the USA, Canada and Australia have decided to withhold or withdraw market authorization, while it is available over-the-counter (OTC) in others [5].…”

Section: Introductionmentioning

confidence: 99%

Regional Differences in Prescribing Patterns of Metamizole in Germany Based on Data from 70 Million Persons

Hoffmann

Bantel

Rosen

et al. 2020

IJERPH

View full text Add to dashboard Cite

The non-opioid analgesic metamizole (dipyrone) is commonly used in Germany despite its narrow indications and market withdrawal from several countries. In this study we analyzed prescribing patterns of metamizole focusing on regional differences. The source of data was the “Information system for health care data” which includes data from the statutory health insurance funds for about 70 million Germans. We received aggregated data of individuals with at least one metamizole prescription in 2010 as well as the number of prescribed packages by age, sex, state and district along with the number of insured persons in each stratum. We calculated prescription prevalence stratified by age, sex, state and district. Among 68.4 million insured persons (mean age: 43.6 years; 53.0% female) 5.5 million received at least one metamizole prescription (8.1%, overall 12.2 million packages). Prevalence increased with age, and women received metamizole more often than men. In adults (total prevalence: 9.4%), levels varied between 7.0% (Saxony) and 11.1% (Schleswig-Holstein), whereas on a district level use ranged from 4.3% to 14.3%. In 2010, one of 12 individuals received metamizole at least once. Noticeable were the large regional variations which certainly cannot be explained by patient-related factors.

show abstract

Section: Introductionmentioning

confidence: 99%

Regional Differences in Prescribing Patterns of Metamizole in Germany Based on Data from 70 Million Persons

Hoffmann

Bantel

Rosen

et al. 2020

IJERPH

View full text Add to dashboard Cite

show abstract

“…Metamizole is generally well tolerated, but in very rare cases serious lifethreatening complications such as agranulocytosis or allergic reactions can occur, which in the worst case can culminate in anaphylactic shock. 12 The Drug Commission of the German Medical Association (AkdA) recommends that the application can only be made within the scope of its approval and only after extensive clarification of the patient about the risks and possible adverse effects such as fever/chills, fatigue, sore throat and inflammation in the area of the oral mucous membranes. In addition, it recommends that wherever there is a suspicion of agranulocytosis, or wherever the agent has been taken for a long time, blood counts should be performed.…”

Section: Analgesicsmentioning

confidence: 99%

“…In addition, it recommends that wherever there is a suspicion of agranulocytosis, or wherever the agent has been taken for a long time, blood counts should be performed. 12,13 Due to its potentially life-threatening complications, the indications of metamizole are restricted to acute and chronic pain when other therapeutic measures are not indicated. 14 As such there are only a few cases where a short-term use of metamizole for the treatment of OA pain can actually be considered.…”

Section: Analgesicsmentioning

confidence: 99%

Pharmacological treatment of knee osteoarthritis: Special considerations of the new German guideline

Steinmeyer¹,

Bock²,

Stöve³

et al. 2018

Orthop Rev (Pavia)

View full text Add to dashboard Cite

The pharmacological treatment of knee osteoarthritis (OA) is a purely symptomatic therapy, which often ensures that the mobility of the patient is successfully retained. This article refers to the recommendations and opinions regarding the pharmacotherapy of knee OA contained in the new guideline of the Association of the Scientific Medical Societies in Germany (AWMF), highlighting several important aspects and describing the considerations underlying the decision-making process. With this article it is hoped that therapeutic effectiveness can be realistically estimated, that any risks of medication errors and avoidable side effects can be reduced, and that further helpful measures can be taken into consideration.

show abstract

“…Dies hat aber zur Nichtzulassung u. a. in den USA und Skandinavien geführt. In der Mehrzahl der publizierten Fälle trat die Granulopenie sehr rasch innerhalb von 3 -14 Tagen auf, sehr selten später als 8 Wochen [3]. Darum ist zu beachten:…”

Section: Metamizolunclassified